Shao-Lee Lin, Acelyrin CEO (Vanja Sabic/Nasdaq, Inc)

Q&A: Ace­lyrin CEO Shao-Lee Lin de­tails biotech's $540M IPO, find­ing 'di­a­monds in the rough'

Ace­lyrin start­ed trad­ing on the Nas­daq Fri­day morn­ing in one of the largest biotech ini­tial pub­lic of­fer­ings in re­cent mem­o­ry, with $540 mil­lion in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.